Bright Minds Biosciences Appoints Stephen Collins As CMO
(RTTNews) - Bright Minds Biosciences, Inc. (DRUG), a company focused on drug-resistant epilepsy, depression, and other central nervous system disorders, said on Tuesday that it has appointed Stephen D. Collins as Chief Medical Officer with immediate effect.
The company has also announced that Mark A. Smith will retire from his role as Acting CMO but will continue to serve in an advisory capacity.
Prior to joining Bright Minds, Collins simultaneously served as CEO of Biscayne Neurotherapeutics and CEO of Biscayne Pharmaceuticals, which was sold to Supernus Pharmaceuticals in 2018.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.